G. Robinet

14.3k total citations · 1 hit paper
110 papers, 3.0k citations indexed

About

G. Robinet is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, G. Robinet has authored 110 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Pulmonary and Respiratory Medicine, 82 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in G. Robinet's work include Lung Cancer Treatments and Mutations (74 papers), Lung Cancer Research Studies (48 papers) and Cancer Immunotherapy and Biomarkers (20 papers). G. Robinet is often cited by papers focused on Lung Cancer Treatments and Mutations (74 papers), Lung Cancer Research Studies (48 papers) and Cancer Immunotherapy and Biomarkers (20 papers). G. Robinet collaborates with scholars based in France, United States and Italy. G. Robinet's co-authors include M. Pérol, A. Vergnenègre, P. Thomas, P. Fournel, Fabrice Barlési, H. Léna, H. Léna, F. Mornex, D. Paillotin and Rodryg Ramlau and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and CHEST Journal.

In The Last Decade

G. Robinet

104 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

2013 370 citations David R. Spigel, Thomas J. Ervin et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Robinet France	23	2.3k	2.1k	522	325	240	110	3.0k
Michael McCleod United States	17	1.7k 0.7×	2.5k 1.2×	410 0.8×	276 0.8×	241 1.0×	44	3.0k
Davey B. Daniel United States	19	2.1k 0.9×	2.2k 1.1×	538 1.0×	688 2.1×	194 0.8×	82	3.3k
Annetta Krebs United States	8	1.9k 0.8×	2.0k 0.9×	723 1.4×	395 1.2×	83 0.3×	8	2.8k
Panos Fidias United States	25	1.8k 0.8×	1.7k 0.8×	925 1.8×	276 0.8×	84 0.3×	58	3.0k
Vera Gorbounova Russia	13	1.8k 0.8×	2.2k 1.1×	617 1.2×	354 1.1×	156 0.7×	23	3.2k
David A. Ramies United States	18	2.9k 1.2×	2.7k 1.3×	1.2k 2.3×	608 1.9×	288 1.2×	37	3.8k
Russell F. DeVore United States	17	2.4k 1.0×	2.8k 1.3×	1.3k 2.4×	460 1.4×	233 1.0×	29	3.8k
Andrew Weickhardt Australia	23	2.3k 1.0×	2.3k 1.1×	967 1.9×	527 1.6×	160 0.7×	111	3.4k
Venice Archer United Kingdom	9	3.6k 1.6×	3.6k 1.7×	919 1.8×	663 2.0×	183 0.8×	16	4.6k
Ichiro Takata Japan	12	2.7k 1.2×	2.3k 1.1×	795 1.5×	345 1.1×	66 0.3×	50	3.4k

Countries citing papers authored by G. Robinet

Since Specialization

Citations

This map shows the geographic impact of G. Robinet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Robinet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Robinet more than expected).

Fields of papers citing papers by G. Robinet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Robinet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Robinet. The network helps show where G. Robinet may publish in the future.

Co-authorship network of co-authors of G. Robinet

This figure shows the co-authorship network connecting the top 25 collaborators of G. Robinet. A scholar is included among the top collaborators of G. Robinet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Robinet. G. Robinet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vergnenègre, A., I. Monnet, Charles Ricordel, et al.. (2023). Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo). Lung Cancer. 178. 191–197. 5 indexed citations

Ricordel, Charles, R. Corre, François Lucia, et al.. (2023). Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29). Translational Lung Cancer Research. 12(2). 266–276. 3 indexed citations

Hémon, Patrice, G. Robinet, R. Descourt, et al.. (2021). 71P Searching for predictive biomarkers of efficacy in small cell lung cancer (SCLC) patients treated with chemotherapy-immunotherapy combination using imaging mass cytometry (the HYPE study). Annals of Oncology. 32. S386–S386. 4 indexed citations

Besse, Benjamin, Jessica Menis, Paolo Bironzo, et al.. (2020). LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer. Annals of Oncology. 31. S1211–S1212. 18 indexed citations

Giaccone, Giuseppe, Enriqueta Felip, Manuel Cobo, et al.. (2020). 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial. Annals of Oncology. 31. S814–S815. 9 indexed citations

Geier, Margaux, et al.. (2020). A 60-Year-Old Woman With Recurrent Hemoptysis. CHEST Journal. 158(6). e273–e277.

Reck, Martin, Leora Horn, Silvia Novello, et al.. (2019). Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(4). 701–711. 50 indexed citations

Geier, Margaux, R. Descourt, R. Corre, et al.. (2018). Real life second-line nivolumab in advanced non-small cell lung cancer: A French observational multicenter study of 259 patients (ABCT-IMMUNOBZH). 2(5). 5 indexed citations

Geier, Margaux, R. Descourt, R. Corre, et al.. (2018). MA08.10 Real-Life Intracerebral Efficacy of Nivolumab in Non-Small Cell Lung Cancer Patients with Brain Metastases. Journal of Thoracic Oncology. 13(10). S384–S385. 10 indexed citations

10.

Besse, Benjamin, Fabrice Barlési, Ingel Demedts, et al.. (2018). 135O A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer. Journal of Thoracic Oncology. 13(4). S76–S76. 1 indexed citations

11.

Quéré, Gilles, R. Descourt, G. Robinet, et al.. (2016). Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer. BMC Cancer. 16(1). 210–210. 26 indexed citations

12.

Chouaïd, C., et al.. (2016). Targeted therapy for localized non-small-cell lung cancer: a review. OncoTargets and Therapy. Volume 9. 4099–4104. 22 indexed citations

13.

Gervais, Radj, G. Robinet, Christelle Clément-Duchêne, et al.. (2013). Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial. Lung Cancer. 80(2). 185–190. 27 indexed citations

14.

Spigel, David R., Thomas J. Ervin, Rodryg Ramlau, et al.. (2011). Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.. Journal of Clinical Oncology. 29(15_suppl). 7505–7505. 149 indexed citations

15.

Vergnenègre, A., R. Corre, H. Bérard, et al.. (2010). Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed: The GFPC 05-06 Study. Journal of Thoracic Oncology. 6(1). 161–168. 27 indexed citations

16.

Chouaïd, C., I. Monnet, G. Robinet, et al.. (2007). Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis. Current Medical Research and Opinion. 23(7). 1509–1515. 21 indexed citations

17.

Cortot, Alexis B., L. Gérinière, G. Robinet, et al.. (2006). Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Annals of Oncology. 17(9). 1412–1417. 35 indexed citations

18.

Chouaïd, C., I. Monnet, G. Robinet, et al.. (2005). P-320 Gefitinib therapy of advanced non small-cell lung cancer (NSCLC): A Markov model-based economic analysis. Lung Cancer. 49. S199–S200. 1 indexed citations

19.

Pérol, M., H. Léna, P. Thomas, et al.. (2002). Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin–vinorelbine with a cisplatin–vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study. Annals of Oncology. 13(5). 742–747. 16 indexed citations

20.

Gatzemeier, U., J P Kleisbauer, P. Drings, et al.. (2000). Lenograstim as Support for ACE Chemotherapy of Small-Cell Lung Cancer. American Journal of Clinical Oncology. 23(4). 393–400. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact